Cargando…
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
BACKGROUND: Obesity is a risk factor for breast cancer (BC) development, recurrence, and death. In view of this, we aimed to investigate the clinical value of obesity in BC patients treated with anti-HER2 therapies in the NeoALTTO trial, which randomized 455 patients to neo-adjuvant lapatinib, trast...
Autores principales: | Di Cosimo, Serena, Porcu, Luca, Agbor-tarh, Dominique, Cinieri, Saverio, Franzoi, Maria Alice, De Santis, Maria Carmen, Saura, Cristina, Huober, Jens, Fumagalli, Debora, Izquierdo, Miguel, Piccart, Martine, Daidone, Maria Grazia, de Azambuja, Evandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590445/ https://www.ncbi.nlm.nih.gov/pubmed/33109233 http://dx.doi.org/10.1186/s13058-020-01356-w |
Ejemplares similares
-
What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
por: Pizzamiglio, Sara, et al.
Publicado: (2021) -
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
por: Chumsri, Saranya, et al.
Publicado: (2022) -
End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO
por: Di Cosimo, Serena, et al.
Publicado: (2023) -
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials
por: Rediti, Mattia, et al.
Publicado: (2023) -
An RB-1 loss of function gene signature as a tool to predict response
to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO
trial (BIG 1-06)
por: Risi, Emanuela, et al.
Publicado: (2019)